ABIO ARCA biopharma, Inc. Stock Quote

ABIO [NASD]

Index	-	P/E	-	EPS (ttm)	-2.65	Insider Own	0.40%	Shs Outstand	9.32M	Perf Week	-2.14%
Market Cap	37.08M	Forward P/E	-	EPS next Y	-	Insider Trans	353.17%	Shs Float	9.28M	Perf Month	-9.25%
Income	-5.80M	PEG	-	EPS next Q	-	Inst Own	8.90%	Short Float	1.29%	Perf Quarter	-3.51%
Sales	-	P/S	-	EPS this Y	59.80%	Inst Trans	4.84%	Short Ratio	0.12	Perf Half Y	-19.06%
Book/sh	8.35	P/B	0.49	EPS next Y	-	ROA	-29.30%	Target Price	-	Perf Year	12.26%
Cash/sh	5.68	P/C	0.73	EPS next 5Y	-	ROE	-31.30%	52W Range	2.21 - 22.00	Perf YTD	2.74%
Dividend	-	P/FCF	-	EPS past 5Y	41.30%	ROI	-	52W High	-81.27%	Beta	2.83
Dividend %	-	Quick Ratio	34.00	Sales past 5Y	-	Gross Margin	-	52W Low	86.43%	ATR	0.37
Employees	9	Current Ratio	34.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	40.56	Volatility	10.56% 7.85%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	56.70%	Profit Margin	-	Rel Volume	1.91	Prev Close	3.98
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	1.02M	Price	4.12
Recom	-	SMA20	-12.56%	SMA50	-8.27%	SMA200	-21.83%	Volume	1,937,401	Change	3.52%

Feb-27-18

Initiated

Ascendiant Capital Markets

Buy

Oct-09-13

Initiated

Dawson James

Buy

$3.75

Feb-13-21 01:09AM	Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation Simply Wall St.
Dec-15-20 08:30AM	ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19 GlobeNewswire
Dec-09-20 05:40PM	ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders GlobeNewswire
Nov-23-20 12:28PM	ARCA Biopharma gets Fast Track designation for experimental COVID-19 treatment MarketWatch +7.46%
08:30AM	AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation GlobeNewswire
Nov-02-20 08:30AM	ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire +5.19%
Oct-07-20 08:30AM	ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19 GlobeNewswire -8.49%
Oct-05-20 04:30PM	ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality GlobeNewswire
Sep-21-20 08:00AM	ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19 GlobeNewswire -10.62%
Aug-17-20 08:49AM	We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth Simply Wall St.
Aug-12-20 08:00AM	ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201 as a Potential Treatment for Severe COVID-19 ACCESSWIRE -7.51%
Aug-05-20 04:15PM	Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Jul-07-20 08:30AM	SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators GlobeNewswire
Jun-03-20 09:56AM	ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering GlobeNewswire -5.39%
09:56AM	Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More Zacks
Jun-01-20 08:20AM	ARCA Biopharma Announces $9.4 Million Registered Direct Offering GlobeNewswire -26.98%
May-29-20 12:24PM	A Mighty May: Over $200,000 In Gross Profits Benzinga -34.41%
09:59AM	Company News for May 29, 2020 Zacks
May-28-20 04:19PM	Arca Biopharma Nearly Quintuples On Plans To Test A Coronavirus Drug Investor's Business Daily +386.33%
12:14PM	Arca Biopharma Stock Triples On Plans To Test A Coronavirus Treatment Investor's Business Daily
10:27AM	Price Over Earnings Overview: ARCA biopharma Benzinga
08:00AM	ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy GlobeNewswire
May-07-20 08:30AM	Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions GlobeNewswire
May-06-20 04:30PM	ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update GlobeNewswire
Feb-18-20 04:30PM	ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update GlobeNewswire
Feb-01-20 08:31AM	Does Market Volatility Impact ARCA biopharma, Inc.'s (NASDAQ:ABIO) Share Price? Simply Wall St.
Nov-06-19 04:10PM	ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Nov-03-19 08:47AM	Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Invest In Growth? Simply Wall St.
Sep-12-19 08:30AM	ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium GlobeNewswire
Sep-11-19 08:30AM	Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting GlobeNewswire +13.16%
Sep-04-19 01:37PM	Could The ARCA biopharma, Inc. (NASDAQ:ABIO) Ownership Structure Tell Us Something Useful? Simply Wall St.
Aug-21-19 09:49AM	INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abiomed, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire +8.08%
Aug-01-19 04:30PM	ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire -7.30%
Jun-04-19 07:09AM	One Thing To Remember About The ARCA biopharma, Inc. (NASDAQ:ABIO) Share Price Simply Wall St.
May-13-19 09:00AM	ARCA biopharma Announces Submission of Patent Application to U.S. Patent and Trademark Office Covering Treatment of Atrial Fibrillation in Patients With Heart Failure GlobeNewswire -10.00%
May-08-19 04:30PM	ARCA Biopharma Announces First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire +20.03%
May-01-19 08:30AM	GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure GlobeNewswire +98.64%
Apr-23-19 08:30AM	ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial GlobeNewswire
Mar-18-19 08:30AM	Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology GlobeNewswire
Mar-06-19 08:00AM	Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine GlobeNewswire
Feb-27-19 04:15PM	ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Feb-20-19 07:30AM	ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug GlobeNewswire +31.27%
Jan-16-19 08:30AM	Zosano Appoints Linda Grais M.D., J.D. to Board of Directors GlobeNewswire
Dec-26-18 11:47AM	ARCA biopharma, Inc. (NASDAQ:ABIO) Insiders Have Been Selling Simply Wall St. -7.06%
Dec-20-18 04:01PM	ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial GlobeNewswire -25.26%
Nov-14-18 04:30PM	ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire -6.94%
Nov-12-18 08:30AM	GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions GlobeNewswire
Nov-05-18 08:30AM	ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions GlobeNewswire +13.17%
Oct-10-18 04:16PM	Westminster biotech company receives second extension on delisting notice from Nasdaq American City Business Journals -5.43%
Oct-02-18 08:00AM	Today's Research Reports on Trending Tickers: ARCA biopharma and Nektar Therapeutics ACCESSWIRE -35.29%
Sep-18-18 08:30AM	ARCA biopharma Submits Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial GlobeNewswire
Aug-09-18 04:15PM	ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Aug-03-18 09:45AM	Marijuana Stocks: Biotech Stock Report: 3 Companies To Watch In August 2018 ACCESSWIRE
Jul-31-18 12:15PM	3 Biotech Stocks in Focus on Tuesday ACCESSWIRE
08:30AM	ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation GlobeNewswire
08:10AM	Todays Research Reports on Stocks to Watch: Progenics Pharmaceuticals and Arca Biopharma ACCESSWIRE
Jun-19-18 07:05AM	Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks ACCESSWIRE
May-29-18 08:30AM	GENETIC-AF Phase 2B Clinical Trial Results Presented in Late Breaking Presentation at European Society of Cardiology Heart Failure 2018 World Congress GlobeNewswire -15.87%
May-11-18 08:20AM	Todays Research Reports on Stocks to Watch: vTv Therapeutics and ARCA Biopharma ACCESSWIRE
May-10-18 08:30AM	ARCA biopharma Announces Phase 2B GENETIC-AF Clinical Trial Results Selected for Late Breaking Oral Presentation at European Society of Cardiology Heart Failure 2018 World Congress GlobeNewswire
07:15AM	Free Technical Insights on Aimmune Therapeutics and Three More Biotech Stocks ACCESSWIRE
May-08-18 04:15PM	ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate Update GlobeNewswire
Apr-23-18 08:30AM	ARCA biopharma and Medtronic Extend Gencaro Clinical Trial Collaboration Agreement GlobeNewswire
Apr-03-18 07:20AM	Blog Exposure - Insmed Announced Submission of New Drug to FDA for Patients with Nontuberculous Mycobacterial Lung Disease ACCESSWIRE
Mar-22-18 04:30PM	ARCA biopharma Announces Fiscal Year 2017 Financial Results and Provides Corporate Update GlobeNewswire
Feb-27-18 03:00PM	Heres Why Arca Biopharma Inc (ABIO) Shares Are Skyrocketing Today SmarterAnalyst
Feb-26-18 02:18PM	ARCA biopharma And ObsEva Just Put Out Clinical Trial Data Market Exclusive
08:00AM	ARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical Trial GlobeNewswire
Jan-23-18 05:13PM	One Thing To Consider Before Buying ARCA biopharma Inc (NASDAQ:ABIO) Simply Wall St.
Jan-08-18 08:30AM	ARCA biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial GlobeNewswire
Jan-02-18 05:09PM	What You Must Know About ARCA biopharma Incs (NASDAQ:ABIO) Major Investors Simply Wall St.
Dec-08-17 06:13PM	Interested In Healthcare? Why ARCA biopharma Inc (ABIO) May Be The Entry Point Simply Wall St.
Nov-30-17 02:25PM	How Much is ARCA biopharma Incs (ABIO) CEO Getting Paid? Simply Wall St.
Nov-20-17 08:05AM	ARCA Biopharma, European Patent for Gencaro and Q3 Review ACCESSWIRE
Nov-17-17 08:10AM	Todays Research Reports on Stocks to Watch: ARCA biopharma and Amicus Therapeutics ACCESSWIRE
Nov-16-17 08:30AM	ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting GlobeNewswire
Nov-09-17 04:05PM	ARCA biopharma Announces Third Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Oct-23-17 08:16PM	ARCA biopharma Inc (ABIO): How Does It Impact Your Portfolio? Simply Wall St.
Sep-21-17 08:30AM	ARCA biopharma to Present at the Sidoti & Company Fall 2017 Conference GlobeNewswire
Aug-16-17 08:30AM	ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial GlobeNewswire
Aug-09-17 04:30PM	ARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim Analysis GlobeNewswire
Aug-03-17 04:15PM	ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Jun-20-17 08:30AM	ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis DSMB Recommendation Anticipated in August 2017 GlobeNewswire
May-15-17 08:30AM	ARCA Biopharma Announces First Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Apr-26-17 08:30AM	ARCA biopharma Announces 200th Patient Randomized into the GENETIC-AF Seamless Design Phase 2B/3 Clinical Trial Business Wire
Apr-18-17 08:30AM	ARCA biopharma to Present at the Planet MicroCap Showcase 2017 Investor Conference Business Wire
Mar-25-17 01:04PM	ARCA BIOPHARMA, INC. Financials
Mar-21-17 04:46PM	ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
04:30PM	ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business Update Business Wire
04:10PM	ARCA BIOPHARMA, INC. Files SEC form 10-K, Annual Report
Mar-06-17 04:32PM	ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM	ARCA biopharma Announces 175th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial Business Wire
Mar-01-17 04:47PM	ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Feb-21-17 08:46AM	ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
08:30AM	Anders Hove, MD Joins ARCA biopharma Board of Directors Business Wire
Jan-18-17 04:32PM	ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM	ARCA biopharma Announces 150th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial Business Wire
Jan-11-17 04:54PM	ARCA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit
Jan-04-17 08:30AM	ARCA biopharma to Present at Biotech Showcase 2017 Business Wire
Dec-20-16 02:26PM	Hedge Funds Arent Crazy About A. M. Castle & Co (CASL) Anymore Insider Monkey

ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CONWAY ROBERT E	Chairman of the Board	Dec 18	Buy	4.16	10,000	41,630	30,000	Dec 21 04:15 PM
CONWAY ROBERT E	Chairman of the Board	Sep 25	Buy	4.28	5,000	21,399	20,000	Sep 25 04:20 PM
CONWAY ROBERT E	Chairman of the Board	Sep 22	Buy	4.66	3,056	14,241	15,000	Sep 24 04:20 PM
CONWAY ROBERT E	Chairman of the Board	Sep 21	Buy	4.77	10,000	47,660	11,944	Sep 21 05:00 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience